Citi analyst Geoff Meacham raised the firm’s price target on Vertex Pharmaceuticals (VRTX) to $585 from $575 and keeps a Buy rating on the shares. The company reported positive Phase 3 data for povetacicept in proteinuria, the analyst tells investors in a research note. Citi upped its estimates for the povetacicept program, seeing broad usage potential.
Meet Samuel – Your Personal Investing Prophet
- Start a conversation with TipRanks’ trusted, data-backed investment intelligence
- Ask Samuel about stocks, your portfolio, or the market and get instant, personalized insights in seconds
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on VRTX:
- Vertex Pharmaceuticals initiated with a Buy at Jefferies
- Vertex Pharmaceuticals: Upgraded Confidence in Povetacicept Drives Strengthened Buy Thesis After Robust Phase III RAINIER Data in IgA Nephropathy
- Vertex Pharmaceuticals up 7% at $492 after positive Povetacicept results
- Vertex Pharmaceuticals announces positive week 36 results in Povetacicept study
- Vertex says JOURNAVX demonstrates ‘effective’ pain management in study